

---

## LETTER TO THE EDITOR

---

### In reference to WKA Yung (*Neuro-Oncology* 2012; 14:1115)

Dear Editor:

As I am very interested in bibliometrics and editorial management, I carefully read your recently published editorial<sup>1</sup> and I thought I could complement the information you provided, which might be of interest to your readers.

From 2007 to 2011, a total of 6055 documents were published by *Neuro-Oncology* according to the Web of Science. Excluding meeting abstracts (5539) and corrections (5), 83.7% of these documents had been cited at least once in their lifetime, which is very outstanding for any journal. In fact, 3 articles<sup>2–4</sup> have been cited more than 100 times each, by articles published in journals such as *Lancet Oncology* (impact factor [IF]: 22.589), the *Journal of the National Cancer Institute* (IF: 13.753), *Nature Clinical Practice Oncology* (IF: 8.000), *Cancer Research* (IF: 7.856), *Clinical Cancer Research* (IF: 7.742), and *Annals of Oncology* (IF: 6.425). The fact that researchers publishing in the top 20 oncology journals use information extracted from *Neuro-Oncology* undoubtedly endorses the quality of the research being printed here.

Another important aspect to consider is the internationality of the journal. In the 5-year period, the country that contributed the most was the United States, with 46.4% of the published documents, followed by Germany (7.5%), Canada (6.5%), Japan (3.6%), and England (2.4%). This information is relevant for researchers who are interested in communicating their research to a wide-ranging audience.

Finally, an indicator of quality is reflected by the use of self-cites. Various articles have covered the topic of

“impact factor manipulation” through the use of self-cites to the same journal.<sup>5,6</sup> Well, *Neuro-Oncology* should be very proud that only 4% of the 1156 cites used to estimate its 2011 IF corresponded to self-citations.

The only thing left to say is congratulations to the editorial team for a job well done. I have no doubt that the sustained growth observed in the past 3 years will allow this journal to reach new heights.

Erwin Krauskopf

*Facultad de Ciencias Biológicas, Universidad Andres Bello, Republica 239 Segundo Piso, Santiago, Chile; Fundacion Ciencia & Vida, Zanartu 1482, Santiago, Chile*

### References

1. Yung WKA. New impact factor reflects increased quality. *Neuro-Oncology*. 2012;14:1115.
2. Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. *Neuro-Oncology*. 2009;11:341–347.
3. Lamborn KR, Yung WKA, Chang SM, et al. Progression-free survival: an important end point for recurrent high-grade gliomas. *Neuro-Oncology*. 2008;10:162–170.
4. Ballman KV, Buckner JC, Brown PD, et al. The relationship between six-month progression-free survival and 12 month overall survival end points for phase II trials in patients with glioblastoma multiforme. *Neuro-Oncology*. 2007;9:39–38.
5. Krauss J. Journal self-citation rates in ecological sciences. *Scientometrics*. 2007;73:79–89.
6. Falagas ME, Alexiou VG. The top-ten in journal impact factor manipulation. *Arch Immunol Ther Exp*. 2008;56:223–226.